Volume : 09, Issue : 08, August – 2022
Title:
37.THE CLINICAL AND REGULATORY STATUS OF BIOSIMILARS
Authors :
Arokiya Pani Selciya. A, Reeta. M, Vigneshwaran. L.V, Senthil Kumar. M*
Abstract :
Pharmaceutical businesses, both based and generic, are vying for the chance to develop new products. Biosimilars are “generic” versions of original biologics. However, the procedure of launching a biosimilar to an innovator product is significantly more complicated than the process of introducing a biosimilar to an existing product. The procedure of introducing a generic copy to an innovator product is quite basic. Predicated on the discovery of a novel chemical entity. Biosimilars aren’t allowed to be referred Generics are a type of medication that is used to treat a wide range of words used to describe pharmaceutical goods that signify “Similarity” between products.
Keywords: Biosimilars, Clinical trials, Regulatory science.
Cite This Article:
Please cite this article in press Senthil Kumar.M et al, The Clinical And Regulatory Status Of Biosimilars., Indo Am. J. P. Sci, 2022; 09(8).
,
Number of Downloads : 10
References:
1)Sekhon BS, Saluja V. Biosimilars: an overview. Biosimilars. 2011 Mar 15;1:1-1.
2)Covic A, Cannata-Andia J, Cancarini G, Coppo R, Frazao JM, Goldsmith D, Ronco P, Spasovski GB, Stenvinkel P, Utas C, Wiecek A. Biosimilars and biopharmaceuticals: what the nephrologists need to know—a position paper by the ERA-EDTA Council. Nephrology Dialysis Transplantation. 2008 Dec 1;23(12):3731-7.
3)Crommelin D, Bermejo T, Bissig M, Damian’s J, Krämer I, Rambourg P. Pharmaceutical evaluation of biosimilars: important differences from generic low-molecular-weight pharmaceuticals. Eur J Hosp Pharm Sci. 2005;11(1):11-7.
4)Schellekens H. Follow-on biologics: challenges of the ‘next generation’. Nephrology Dialysis Transplantation. 2005 May 1;20(suppl_4):iv31-6.
5)Sekhon BS, Saluja V. Biosimilars: an overview. Biosimilars. 2011 Mar 15;1:1-1.
6)therapy, 11, p.1509.
Schiestl M, Zabransky M, Sörgel F. Ten years of biosimilars in Europe: development and evolution of the regulatory pathways. Drug design, development, and therapy. 2017;11:1509
7)Luo J, Kesselheim AS, Sarpatwari A. Insulin access and affordability in the USA: anticipating the first interchangeable insulin product. The Lancet Diabetes & Endocrinology. 2020 May 1;8(5):360-2.
8)Naito C. Ethnic factors in the acceptability of foreign clinical data. Drug information journal. 1998 Oct;32(1_suppl):1283S-92S.
BibTeX EndNote RefMan RefWorks.
9)Klein AV, Wang J, Feagan BG, Omoto M. Biosimilars: state of clinical and regulatory science. Journal of Pharmacy & Pharmaceutical Sciences. 2017;20:332-48.
10)Cavagnaro JA. Preclinical safety evaluation of biotechnology-derived pharmaceuticals. Nature Reviews Drug Discovery. 2002 Jun;1(6):469-75.
11)Jørgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm EA, Lundin KE, Mørk C, Jahnsen J, Kvien TK, Berset IP. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomized, double-blind, non-inferiority trial. The Lancet. 2017 Jun 10;389(10086):2304-16.
12)Klein AV, Wang J, Feagan BG, Omoto M. Biosimilars: state of clinical and regulatory science. Journal of Pharmacy & Pharmaceutical Sciences. 2017;20:332-48.
13)Declerck P, Farouk-Rezk M, Rudd PM. Biosimilarity versus manufacturing change: two distinct concepts. Pharmaceutical research. 2016 Feb;33(2):261-8.
14)Lewis PA, Alexander cs. daraprim specialty drug pricing: a case study. southern journal of business and ethics.:134.
15)Scheinberg MA, Kay J. The advent of biosimilar therapies in rheumatology—“O brave new